More than 1 million apheresis platelet collections are performed annually in the United States. After 2 healthy plateletpheresis donors were incidentally found to have low CD4 T-lymphocyte counts, we investigated whether plateletpheresis causes lymphopenia. We conducted a cross-sectional single-center study of platelet donors undergoing plateletpheresis with the Trima Accel, which removes leukocytes continuously with its leukoreduction system chamber. We recruited 3 groups of platelet donors based on the total number of plateletpheresis sessions in the prior 365 days: 1 or 2, 3 to 19, or 20 to 24. CD4 T-lymphocyte counts were <200 cells per microliter in 0/20, 2/20, and 6/20 donors, respectively ( = .019), and CD8 T-lymphocyte counts were low in 0/20, 4/20, and 11/20 donors, respectively ( < .001). The leukoreduction system chamber's lymphocyte-extraction efficiency was ∼15% to 20% for all groups. Immunophenotyping showed decreases in naive CD4 T-lymphocyte and T helper 17 (Th17) cell percentages, increases in CD4 and CD8 effector memory, Th1, and regulatory T cell percentages, and stable naive CD8 and Th2 percentages across groups. T-cell receptor repertoire analyses showed similar clonal diversity in all groups. Donor screening questionnaires supported the good health of the donors, who tested negative at each donation for multiple pathogens, including HIV. Frequent plateletpheresis utilizing a leukoreduction system chamber is associated with CD4 and CD8 T-cell lymphopenia in healthy platelet donors. The mechanism may be repeated extraction of these cells during plateletpheresis. The cytopenias do not appear to be harmful.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367645 | PMC |
http://dx.doi.org/10.1182/blood-2018-09-873125 | DOI Listing |
Transfus Med
January 2025
Research and Development, Finnish Red Cross Blood Service, Vantaa, Finland.
Background: Extracellular vesicles (EVs) have procoagulative properties. As EVs are known to accumulate in stored blood products, we compared the EV content and coagulation capacity of leukoreduced cold-stored whole blood (CSWB) with current prehospital and in-hospital component therapies to understand the role of EVs in the haemostatic capacity of ageing CSWB.
Materials And Methods: Blood was obtained from 12 O RhD-positive male donors.
Glycobiology
January 2025
Institute of Blood Transfusion, Shanghai Blood Center, 1191 Hongqiao Road, Shanghai 200051, China.
Glycosylation is an important posttranslational modification in platelets, and the glycosylation pattern is critical for platelet function. To date, the exploration of the roles of various glycoforms in specific platelet functions is largely lacking. In this study, a global analysis of intact N-glycopeptides in human platelets was performed to map all the glycopeptides, glycosites and glycans of platelets.
View Article and Find Full Text PDFInt J Pharm
January 2025
National Engineering Research Center of Ophthalmology and Optometry, School of Biomedical Engineering, School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou 325027 China. Electronic address:
Maintaining the clarity of the cornea is crucial for optimal vision. Corneal scarring (CS), resulting from corneal inflammation, trauma, or surgery, can lead to a reduction in corneal transparency and visual impairment. While corneal transplantation is the primary method for restoring vision, the limited availability of corneal donor presents a significant challenge on a global scale.
View Article and Find Full Text PDFBiomed Pharmacother
January 2025
Thrombosis and Healthy Aging Research Center, MIBI: Interdisciplinary Group on Mitochondrial Targeting and Bioenergetics, Medical Technology School, Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Talca, Chile. Electronic address:
Platelet inhibition is a fundamental objective to prevent and treat thrombus formation. Platelet activation depends on mitochondrial function. This study aims to identify a new mitochondria-targeting compound with antiplatelet activity at safe concentrations in vitro.
View Article and Find Full Text PDFCureus
December 2024
Department of Clinical Hematology and Bone Marrow Transplant (BMT), Command Hospital, Lucknow, IND.
Background: There is no standard treatment to accelerate recovery from melphalan-induced thrombocytopenia in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT). Romiplostim, a thrombopoietin receptor agonist, has been developed to upregulate platelet production.
Objective: This study aimed to assess the efficacy and safety of romiplostim in reducing platelet transfusions post-ASCT in MM patients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!